Movement Alert｜BeOne Medicines Rises 3.04% in Regular Trading, FDA Acceptance of Tevimbra Esophageal Cancer Application Continues to Catalyze Rebound

Market Focus06-23

On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside a broad biotech sector pullback.

On the news front, BeOne Medicines recently announced that the U.S. FDA accepted its New Drug Application for Tevimbra targeting esophageal squamous cell carcinoma, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, signaling continued fundamental improvement.

Within the Biotechnology sector, the overall sector partially recovered today. Among individual stocks, AKESO up 3.44%, REMEGEN up 3.15%, CARSGEN-B up 1.55%, INNOVENT BIO up 1.26%, providing sector linkage support for the technical rebound in BeOne Medicines.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135097337?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-23 09:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135097337","market":"us","top_or_hot":-1,"title":"Movement Alert｜BeOne Medicines Rises 3.04% in Regular Trading, FDA Acceptance of Tevimbra Esophageal Cancer Application Continues to Catalyze Rebound","media":"Market Focus","content":"<p><p>On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside a broad biotech sector pullback.</p><p>On the news front, BeOne Medicines recently announced that the U.S. FDA accepted its New Drug Application for Tevimbra targeting esophageal squamous cell carcinoma, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, signaling continued fundamental improvement.</p><p>Within the Biotechnology sector, the overall sector partially recovered today. Among individual stocks, AKESO up 3.44%, REMEGEN up 3.15%, CARSGEN-B up 1.55%, INNOVENT BIO up 1.26%, providing sector linkage support for the technical rebound in BeOne Medicines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BeOne Medicines Rises 3.04% in Regular Trading, FDA Acceptance of Tevimbra Esophageal Cancer Application Continues to Catalyze Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BeOne Medicines Rises 3.04% in Regular Trading, FDA Acceptance of Tevimbra Esophageal Cancer Application Continues to Catalyze Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-23 09:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside a broad biotech sector pullback.</p><p>On the news front, BeOne Medicines recently announced that the U.S. FDA accepted its New Drug Application for Tevimbra targeting esophageal squamous cell carcinoma, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, signaling continued fundamental improvement.</p><p>Within the Biotechnology sector, the overall sector partially recovered today. Among individual stocks, AKESO up 3.44%, REMEGEN up 3.15%, CARSGEN-B up 1.55%, INNOVENT BIO up 1.26%, providing sector linkage support for the technical rebound in BeOne Medicines.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百济神州","start_time":0,"source_url":"","article_id":"1135097337","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135097337","pubTimestamp":1782178705,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"动静提示|BeOne Medicines常规交易涨3.04%FDA受理Tevimbra食管癌申请继续催化反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On June 23, BeOne Medicines rose 3.04% in regular trading, trading at 166.1 HKD/share, with turnover of 49.29 million HKD. The stock rebounded after falling over 3% in the previous session alongside a broad biotech sector pullback.On the news front, BeOne Medicines recently announced that the U.S. FDA accepted its New Drug Application for Tevimbra targeting esophageal squamous cell carcinoma, marking a key milestone in the overseas indication expansion of its core PD-1 antibody product. Additionally, the company reported Q1 net profit attributable to shareholders surging 1,801.3% year-over-year, with gross margin approaching 90%, signaling continued fundamental improvement.Within the Biotechnology sector, the overall sector partially recovered today. Among individual stocks, AKESO up 3.44%, REMEGEN up 3.15%, CARSGEN-B up 1.55%, INNOVENT BIO up 1.26%, providing sector linkage support for the technical rebound in BeOne Medicines.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135097337","isCrawlerRequest":true}